title: Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression.
abstract: Tumor relapse after radiotherapy may be due to the upregulation of programmed cell death ligand 1 (PD-L1). We demonstrated that anti-PD-L1 antibody synergizes with radiation to control local and distal tumors. CD8+T cells mediated antitumor effects of the combination therapy by the reduction of myeloid-derived suppressor cells (MDSCs) via tumor-necrosis factor (TNF)-mediated signaling. Our study provides insight into immune- and radiation-based combinational therapies.
authors: Department of Radiation and Cellular Oncology; The Ludwig Center for Metastasis Research; University of Chicago, Chicago, IL USA.
authors: Liufu
authors: L
authors: Deng
authors: Department of Radiation and Cellular Oncology; The Ludwig Center for Metastasis Research; University of Chicago, Chicago, IL USA.
authors: Hua
authors: H
authors: Liang
authors: Department of Radiation and Cellular Oncology; The Ludwig Center for Metastasis Research; University of Chicago, Chicago, IL USA.
authors: Byron
authors: B
authors: Burnette
authors: Department of Radiation and Cellular Oncology; The Ludwig Center for Metastasis Research; University of Chicago, Chicago, IL USA.
authors: Ralph R
authors: RR
authors: Weicheslbaum
authors: Department of Pathology; University of Chicago, Chicago, IL USA.
authors: Yang-Xin
authors: YX
authors: Fu
keywords: PD-L1; T-cell activation; TNF; antibody therapy; myeloid-derived suppressor cell; negative signal; radiation therapy